3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
11
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Ovarian Neoplasms
40
Breast Neoplasms
14
Uterine Cervical Neoplasms
13
Melanoma
13
Carcinoma, Non-Small-Cell Lung
13
Pancreatic Neoplasms
11
Colorectal Neoplasms
10
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Stomach Neoplasms
7
Triple Negative Breast Neoplasms
6
Fallopian Tube Neoplasms
6
Esophageal Neoplasms
6
Anus Neoplasms
6
Vaginal Neoplasms
5
Penile Neoplasms
5
Lung Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Carcinoma, Hepatocellular
5
Vulvar Neoplasms
4
Urogenital Neoplasms
4
Urinary Bladder Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma, Synovial
4
Oropharyngeal Neoplasms
4
Neoplasms
4
Multiple Myeloma
4
Mesothelioma
4
Carcinoma, Renal Cell
4
Recurrence
3
Interventions
pembrolizumab
4
Paclitaxel
3
Bevacizumab
3
fludarabine
2
Nivolumab
2
Drug Therapy
2
Cyclophosphamide
2
Azacitidine
2
vocimagene amiretrorepvec
1
ulixertinib
1
spartalizumab
1
sapanisertib
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
ridaforolimus
1
regorafenib
1
pazopanib
1
motexafin gadolinium
1
lenvatinib
1
epacadostat
1
cobimetinib
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
aflibercept
1
abiraterone
1
Uncertainty
1
Sirolimus
1
Quality of Life
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Glioblastoma
×
fludarabine
×
Gynecologic
×
Clear all
NCT07523529
2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2
Recruiting
72 enrolled
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled